What makes GHK-Cu different from KPV?

Both are small tripeptides that appear in tissue-repair blends, but they operate on completely different biological axes. GHK-Cu (glycyl-histidyl-lysine bound to copper) drives structural remodelling of the extracellular matrix. Its mechanism is broad transcriptional modulation — whole-genome expression profiling has documented that GHK-Cu alters expression of thousands of genes involved in collagen and elastin synthesis, angiogenesis, and wound healing (Pickart 2018). The copper it delivers is the cofactor for lysyl oxidase, the enzyme that cross-links collagen fibres. It is the reason cosmetic dermatology has decades of GHK-Cu literature.

KPV (lysyl-prolyl-valine) is the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone. Its mechanism is inflammatory suppression — specifically, inhibition of NF-κB nuclear translocation, which reduces TNF-α, IL-6, and IL-1β downstream signalling (Kannengiesser 2008). It is a purely anti-inflammatory peptide with no structural-remodelling activity of its own.

In a tissue-repair blend, the two components address different rate-limiting steps. GHK-Cu tells cells what to build. KPV lowers the inflammatory background that would otherwise antagonise the building. When both are combined in Aura (GHK-Cu + BPC-157 + KPV) or Klow (all four tissue-repair peptides), the pharmacological logic is layered rather than redundant. GHK-Cu is contraindicated in Wilson's disease because it delivers copper; KPV does not have this consideration because it is not a copper carrier.